Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Charlie Kirk shot dead
  • Nepal protests
  • Russia-Poland tension
  • Israeli strikes in Qatar
  • Larry Ellison
  • Apple event
  • Sunjay Kapur inheritance row
fp-logo
WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • World
  • WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

Reuters • June 4, 2020, 11:29:22 IST
Whatsapp Facebook Twitter

WHO’s chief scientist said “We owe it to patients to have a definitive answer on whether or not a drug works."

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
WHO will resume its trial of hydroxychloroquine after studies claiming increased death rates are called into question

The World Health Organization will resume its trial of hydroxychloroquine for potential use against the coronavirus, its chief said on Wednesday, after those running the study briefly stopped giving it to new patients over health concerns. The U.N. agency last month paused the part of its large study of treatments against COVID-19 in which newly enrolled patients were getting the anti-malarial drug to treat COVID-19 due to fears it increased **death rates and irregular heartbeats** . The study continued with other medicines. [caption id=“attachment_8442541” align=“alignnone” width=“1280”] ![This Monday, April 6, 2020 file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. On Tuesday, June 2, 2020, concerns are mounting about studies in two influential medical journals on drugs used in people with coronavirus, including one that led multiple countries to stop testing a malaria pill. (AP Photo/John Locher,File)](https://images.firstpost.com/wp-content/uploads/2020/06/AP20154680815145-1.jpg) A file photo shows an arrangement of hydroxychloroquine pills in Las Vegas. On Tuesday, June 2, 2020, concerns are mounting about studies in two influential medical journals on drugs used in people with coronavirus, including one that led multiple countries to stop testing a malaria pill. Image credit: AP Photo/John Locher[/caption] But the WHO’s director-general, Tedros Adhanom Ghebreyesus, said its experts had advised the continuation of all trials including hydroxychloroquine, whose highest-profile backer for use against the coronavirus is US President Donald Trump. “The executive group will communicate with the principal investigators in th **e trial about resuming the hydroxychloroquine** arm of the trial,” Tedros told an online media briefing, referring to WHO’s initiative to hold clinical tests of potential COVID-19 treatments on some 3,500 patients in 35 countries. The WHO’s decision to suspend its trial prompted others to follow suit, including Sanofi, which said on 29 May it was suspending recruitment for its trials. A Sanofi spokesman said the company would review available information and run consultations in the coming days to reassess its position following the WHO’s latest decision on Wednesday. The WHO’s chief scientist, Soumya Swaminathan, called for other trials of the drug to proceed. “We owe it to patients to have a definitive answer on whether or not a drug works,” she said, adding that safety monitoring should also continue. Swaminathan said the WHO would be keen to see more results of clinical trials of Avifavir, a drug she said would be used to treat COVID-19 in Russian hospitals “very soon”. In the same virtual briefing, WHO officials said they were especially worried about outbreaks in Latin America and in Haiti, one of the world’s poorest nations, where infections have been spreading rapidly. The coronavirus has infected almost 3 million people in the Americas and more than 6.43 million worldwide. Also Read:  **Hydroxychloroquine sustained dose and PPE can reduce COVID-19 risk in healthcare workers, ICMR study says** **Two studies that showed Hydroxychloroquine's negative effects on COVID-19 patients are being called into question**

Tags
WHO Vaccine Treatment Pandemic cure coronavirus Coronavirus outbreak coronavirus cases Coronavirus lockdown coronavirus testing Frontline Workers easing lockdown restrictions death cases increase in coronavirus cases antibody tests
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

French MPs call for social media ban for under-15s, digital curfew for teenagers

French MPs call for social media ban for under-15s, digital curfew for teenagers

A French committee suggests banning social media for kids under 15 and a nighttime digital curfew for teens 15-18. The report cites concerns about TikTok's effects on minors. President Macron backs the ban, akin to Australia's proposed law.

More Impact Shorts

Top Stories

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV